The antibody discovery services market size has grown rapidly in recent years. It will grow from $2.9 billion in 2025 to $3.24 billion in 2026 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to increasing demand for targeted biologic therapies, expansion of monoclonal antibody drug development, rising outsourcing of R&D by pharmaceutical companies, advancements in hybridoma and phage display techniques, growth in biotechnology research funding.
The antibody discovery services market size is expected to see rapid growth in the next few years. It will grow to $5.07 billion in 2030 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to increasing adoption of AI-powered drug discovery platforms, rising demand for personalized and precision medicine, expansion of biologics and biosimilar development pipelines, growing use of automation in antibody screening processes, and increasing collaborations between biotech companies and CRO service providers. Major trends in the forecast period include automation of high-throughput antibody discovery workflows using robotic systems, cloud-based bioinformatics integration for antibody sequence analysis and optimization, digital twin modeling for antibody-antigen interaction simulation, Industry 4.0-enabled smart biolab automation for accelerated discovery pipelines, and rising demand for precision medicine-driven customized antibody development services.
The increasing adoption of precision medicine and targeted therapies is expected to drive the expansion of the antibody discovery services market going forward. Precision medicine and targeted therapies refer to medical approaches that customize treatments based on individual genetic, molecular, and clinical characteristics to enhance outcomes and minimize adverse effects. The adoption of precision medicine and targeted therapies is rising due to the increasing number of personalized drug approvals, reflecting strong innovation in targeted treatment development. Antibody discovery services facilitate the advancement of precision medicine and targeted therapies by enabling the creation of highly specific antibodies that accurately target disease-related biomarkers and biological pathways, thereby improving treatment precision and effectiveness. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, in 2023, the FDA approved 16 new personalized therapies for patients with rare diseases, compared to just six approvals recorded in 2022. Therefore, the increasing adoption of precision medicine and targeted therapies is driving the growth of the antibody discovery services market.
Key companies operating in the antibody discovery services market are focusing on developing advanced solutions, such as AI-driven antibody discovery workflows, to streamline candidate screening, improve binding validation efficiency, and accelerate lead selection workflows. AI-driven antibody discovery workflows use artificial intelligence and machine learning to accelerate the identification, screening, and optimization of antibody candidates, improving prediction accuracy, reducing development timelines, and enhancing overall research efficiency. For example, in May 2026, Nuclera, a UK-based biotechnology company, launched its antibody triage service to support AI-driven antibody discovery workflows. The service utilizes 96-plex binary cell-free expression and binding assays to screen full-length antibody libraries in parallel and rapidly identify confirmed binders from large AI-generated candidate pools. The platform also integrates Surface Plasmon Resonance (SPR) analysis for binding kinetics evaluation, enabling researchers to reduce non-binder validation costs, improve workflow efficiency, and accelerate progression from antibody hit generation to lead selection.
In December 2023, Danaher Corporation, a US-based life sciences company, acquired Abcam plc for an undisclosed amount. Through this acquisition, Danaher Corporation aimed to strengthen its life sciences portfolio by integrating Abcam plc’s comprehensive antibody reagent capabilities, enhancing support for biopharmaceutical research, and advancing antibody discovery workflows. Abcam plc is a UK-based biotechnology company that provides research-grade antibodies and related reagents for life sciences research, diagnostics, and drug discovery applications.
Major companies operating in the antibody discovery services market are Thermo Fisher Scientific Inc., WuXi AppTec Co. Ltd., Lonza Group AG, Charles River Laboratories, WuXi Biologics (Cayman) Inc., Eurofins Discovery, Evotec SE, GenScript Biotech Corporation, Abcam plc, Syngene International Limited, Twist Bioscience, Sino Biological Inc., OmniAb Inc., FairJourney Biologics S.A., Abzena, Biocytogen Pharmaceuticals (Beijing) Co. Ltd., Genoway S.A., Aurigene Pharmaceutical Services Limited, Adimab LLC, Harbour BioMed Limited, Absolute Biotech, Abnova Corporation, Biointron Biological Inc., Creative Biolabs Inc., ProteoGenix SAS, Integral Molecular Inc., Ablexis LLC, Isogenica Limited, MabDiscovery GmbH.
North America was the dominant region in the antibody discovery services market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in antibody discovery services report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antibody discovery services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The antibody discovery services market consists of revenues earned by entities by providing services such as hybridoma development, phage display screening, single B-cell screening, antibody characterization, and profiling. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The antibody discovery services market research report is one of a series of new reports that provides antibody discovery services market statistics, including antibody discovery services industry global market size, regional shares, competitors with a antibody discovery services market share, detailed antibody discovery services market segments, market trends and opportunities, and any further data you may need to thrive in the antibody discovery services industry. This antibody discovery services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
This product will be delivered within 1-3 business days.
The antibody discovery services market size is expected to see rapid growth in the next few years. It will grow to $5.07 billion in 2030 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to increasing adoption of AI-powered drug discovery platforms, rising demand for personalized and precision medicine, expansion of biologics and biosimilar development pipelines, growing use of automation in antibody screening processes, and increasing collaborations between biotech companies and CRO service providers. Major trends in the forecast period include automation of high-throughput antibody discovery workflows using robotic systems, cloud-based bioinformatics integration for antibody sequence analysis and optimization, digital twin modeling for antibody-antigen interaction simulation, Industry 4.0-enabled smart biolab automation for accelerated discovery pipelines, and rising demand for precision medicine-driven customized antibody development services.
The increasing adoption of precision medicine and targeted therapies is expected to drive the expansion of the antibody discovery services market going forward. Precision medicine and targeted therapies refer to medical approaches that customize treatments based on individual genetic, molecular, and clinical characteristics to enhance outcomes and minimize adverse effects. The adoption of precision medicine and targeted therapies is rising due to the increasing number of personalized drug approvals, reflecting strong innovation in targeted treatment development. Antibody discovery services facilitate the advancement of precision medicine and targeted therapies by enabling the creation of highly specific antibodies that accurately target disease-related biomarkers and biological pathways, thereby improving treatment precision and effectiveness. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, in 2023, the FDA approved 16 new personalized therapies for patients with rare diseases, compared to just six approvals recorded in 2022. Therefore, the increasing adoption of precision medicine and targeted therapies is driving the growth of the antibody discovery services market.
Key companies operating in the antibody discovery services market are focusing on developing advanced solutions, such as AI-driven antibody discovery workflows, to streamline candidate screening, improve binding validation efficiency, and accelerate lead selection workflows. AI-driven antibody discovery workflows use artificial intelligence and machine learning to accelerate the identification, screening, and optimization of antibody candidates, improving prediction accuracy, reducing development timelines, and enhancing overall research efficiency. For example, in May 2026, Nuclera, a UK-based biotechnology company, launched its antibody triage service to support AI-driven antibody discovery workflows. The service utilizes 96-plex binary cell-free expression and binding assays to screen full-length antibody libraries in parallel and rapidly identify confirmed binders from large AI-generated candidate pools. The platform also integrates Surface Plasmon Resonance (SPR) analysis for binding kinetics evaluation, enabling researchers to reduce non-binder validation costs, improve workflow efficiency, and accelerate progression from antibody hit generation to lead selection.
In December 2023, Danaher Corporation, a US-based life sciences company, acquired Abcam plc for an undisclosed amount. Through this acquisition, Danaher Corporation aimed to strengthen its life sciences portfolio by integrating Abcam plc’s comprehensive antibody reagent capabilities, enhancing support for biopharmaceutical research, and advancing antibody discovery workflows. Abcam plc is a UK-based biotechnology company that provides research-grade antibodies and related reagents for life sciences research, diagnostics, and drug discovery applications.
Major companies operating in the antibody discovery services market are Thermo Fisher Scientific Inc., WuXi AppTec Co. Ltd., Lonza Group AG, Charles River Laboratories, WuXi Biologics (Cayman) Inc., Eurofins Discovery, Evotec SE, GenScript Biotech Corporation, Abcam plc, Syngene International Limited, Twist Bioscience, Sino Biological Inc., OmniAb Inc., FairJourney Biologics S.A., Abzena, Biocytogen Pharmaceuticals (Beijing) Co. Ltd., Genoway S.A., Aurigene Pharmaceutical Services Limited, Adimab LLC, Harbour BioMed Limited, Absolute Biotech, Abnova Corporation, Biointron Biological Inc., Creative Biolabs Inc., ProteoGenix SAS, Integral Molecular Inc., Ablexis LLC, Isogenica Limited, MabDiscovery GmbH.
North America was the dominant region in the antibody discovery services market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in antibody discovery services report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antibody discovery services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The antibody discovery services market consists of revenues earned by entities by providing services such as hybridoma development, phage display screening, single B-cell screening, antibody characterization, and profiling. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The antibody discovery services market research report is one of a series of new reports that provides antibody discovery services market statistics, including antibody discovery services industry global market size, regional shares, competitors with a antibody discovery services market share, detailed antibody discovery services market segments, market trends and opportunities, and any further data you may need to thrive in the antibody discovery services industry. This antibody discovery services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Antibody Discovery Services Market Characteristics
3. Antibody Discovery Services Market Supply Chain Analysis
4. Global Antibody Discovery Services Market Trends And Strategies
5. Antibody Discovery Services Market Analysis Of End Use Industries
7. Global Antibody Discovery Services Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
8. Global Antibody Discovery Services Total Addressable Market (TAM) Analysis for the Market
9. Antibody Discovery Services Market Segmentation
10. Antibody Discovery Services Market Regional And Country Analysis
11. Asia-Pacific Antibody Discovery Services Market
12. China Antibody Discovery Services Market
13. India Antibody Discovery Services Market
14. Japan Antibody Discovery Services Market
15. Australia Antibody Discovery Services Market
16. Indonesia Antibody Discovery Services Market
17. South Korea Antibody Discovery Services Market
18. Taiwan Antibody Discovery Services Market
19. South East Asia Antibody Discovery Services Market
20. Western Europe Antibody Discovery Services Market
21. UK Antibody Discovery Services Market
22. Germany Antibody Discovery Services Market
23. France Antibody Discovery Services Market
24. Italy Antibody Discovery Services Market
25. Spain Antibody Discovery Services Market
26. Eastern Europe Antibody Discovery Services Market
27. Russia Antibody Discovery Services Market
28. North America Antibody Discovery Services Market
29. USA Antibody Discovery Services Market
30. Canada Antibody Discovery Services Market
31. South America Antibody Discovery Services Market
32. Brazil Antibody Discovery Services Market
33. Middle East Antibody Discovery Services Market
34. Africa Antibody Discovery Services Market
36. Antibody Discovery Services Market Competitive Landscape And Company Profiles
37. Antibody Discovery Services Market Other Major And Innovative Companies
41. Antibody Discovery Services Market High Potential Countries, Segments and Strategies
42. Appendix
Executive Summary
Antibody Discovery Services Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses antibody discovery services market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for antibody discovery services? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The antibody discovery services market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Service: Target Identification And Validation; Antibody Engineering And Optimization; Antigen Design And Production; Immunization And Host Management; Other Services2) By Antibody Type: Monoclonal; Polyclonal; Bispecific; Other Antibody Types
3) By Technology: Phage Display Technology; Hybridoma Technology; Single Cell Technology; Recombinant Deoxyribonucleic Acid Technology; Next Generation Sequencing; Artificial Intelligence Based Discovery
4) By Application: Oncology; Infectious Diseases; Immunology; Other Applications
5) By End User: Pharmaceutical And Biotechnology Companies; Academic And Research Institutes; Contract Research Organizations
Subsegments:
1) By Target Identification And Validation: Genomic Target Identification; Proteomic Target Identification; Biomarker Discovery; Target Validation Assays; Functional Genomics Studies2) By Antibody Engineering And Optimization: Affinity Maturation; Antibody Humanization; Stability Optimization; Fragment Crystallizable Region Engineering; Specificity Enhancement
3) By Antigen Design And Production: Recombinant Antigen Production; Synthetic Peptide Design; Protein Expression Systems; Antigen Purification; Epitope Mapping
4) By Immunization And Host Management: Animal Immunization Services; Host Selection And Management; Immunization Protocol Optimization; Serum Collection And Processing; Hybridoma Generation
5) By Other Services: High Throughput Screening Services; Antibody Characterization Services; Bioinformatics Analysis Services; Antibody Sequencing Services; Custom Antibody Development
Companies Mentioned: Thermo Fisher Scientific Inc.; WuXi AppTec Co. Ltd.; Lonza Group AG; Charles River Laboratories; WuXi Biologics (Cayman) Inc.; Eurofins Discovery; Evotec SE; GenScript Biotech Corporation; Abcam plc; Syngene International Limited; Twist Bioscience; Sino Biological Inc.; OmniAb Inc.; FairJourney Biologics S.A.; Abzena; Biocytogen Pharmaceuticals (Beijing) Co. Ltd.; Genoway S.A.; Aurigene Pharmaceutical Services Limited; Adimab LLC; Harbour BioMed Limited; Absolute Biotech; Abnova Corporation; Biointron Biological Inc.; Creative Biolabs Inc.; ProteoGenix SAS; Integral Molecular Inc.; Ablexis LLC; Isogenica Limited; MabDiscovery GmbH
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
- Thermo Fisher Scientific Inc.
- WuXi AppTec Co. Ltd.
- Lonza Group AG
- Charles River Laboratories
- WuXi Biologics (Cayman) Inc.
- Eurofins Discovery
- Evotec SE
- GenScript Biotech Corporation
- Abcam plc
- Syngene International Limited
- Twist Bioscience
- Sino Biological Inc.
- OmniAb Inc.
- FairJourney Biologics S.A.
- Abzena
- Biocytogen Pharmaceuticals (Beijing) Co. Ltd.
- Genoway S.A.
- Aurigene Pharmaceutical Services Limited
- Adimab LLC
- Harbour BioMed Limited
- Absolute Biotech
- Abnova Corporation
- Biointron Biological Inc.
- Creative Biolabs Inc.
- ProteoGenix SAS
- Integral Molecular Inc.
- Ablexis LLC
- Isogenica Limited
- MabDiscovery GmbH
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | April 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 3.24 Billion |
| Forecasted Market Value ( USD | $ 5.07 Billion |
| Compound Annual Growth Rate | 11.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 29 |
